The present invention relates to novel recombinant antibodies directed against human MET (c-MET), as well as compositions comprising mixtures of at least two of said antibodies and use of the antibodies and antibody compositions for treatment of MET-mediated disorders such as cancer.La présente invention concerne de nouveaux anticorps recombinants dirigés contre le MET humain (c-MET), ainsi que des compositions comportant des mélanges dau moins deux desdits anticorps, et lutilisation de ces anticorps et compositions danticorps pour le traitement de troubles médiés par MET, tels que le cancer.
